# Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

> **NCT02780323** · PHASE4 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CELBESTA®
- **DRUG:** CELEBREX®
- **DRUG:** CELEBREX® placebo
- **DRUG:** CELBESTA® placebo

## Key facts

- **NCT ID:** NCT02780323
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-02
- **Primary completion:** 2017-12-26
- **Final completion:** 2017-12-26
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780323, "Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02780323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*